balovaptan
Small moleculeexperimental
Balovaptan, is a selective small molecule antagonist of the vasopressin V1A receptor which is under development by Roche for the treatment of post-traumatic stress disorder (PTSD). — Wikipedia
Clinical trial activity
10 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jul 10, 2018 (NCT03579719)
Timeline
Indications
Mechanism of action
- Vasopressin V1a receptorANTAGONIST
Vasopressin V1a receptor antagonist
- Vasopressin V1a receptorINHIBITOR
AVPR1A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1Cc2cc(Cl)ccc2-n2c(nnc2[C@H]2CC[C@H](Oc3ccccn3)CC2)C1- Mol. weight
- 409.92 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBalovaptan ↗
- ChEMBLCHEMBL4297183 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05401565 | Phase 2 | Aug 2, 2022 | Roche |
| NCT05399550 | Phase 2 | Jun 22, 2022 | Roche |
| NCT04156646 | Phase 1 | Nov 19, 2019 | Roche |
| NCT04049578 | Phase 1 | Aug 15, 2019 | Roche |
| NCT03912350 | Phase 1 | Jul 25, 2019 | Roche |
| NCT03808298 | Phase 1 | Feb 7, 2019 | Roche |
| NCT03764449 | Phase 1 | Jan 10, 2019 | Roche |
| NCT03504917 | Phase 3 | Aug 8, 2018 | Roche |
| NCT03586726 | Phase 1 | Jul 24, 2018 | Roche |
| NCT03579719 | Phase 1 | Jul 10, 2018 | Roche |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 10 | 10 | 3 | 2018 |
1 organizations
Page 1 / 1